Literature DB >> 1881457

N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines.

K F McKenna1, G B Baker, R T Coutts.   

Abstract

The neurochemical properties of N2-acetylphenelzine were compared with those of phenelzine in a rat model. N2-Acetylphenelzine is a relatively potent inhibitor of monoamine oxidase-A and -B and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p. administration of the drug. Phenelzine is a more potent monoamine oxidase inhibitor than is N2-acetylphenelzine. The most marked difference in the profile was that N2-acetylphenelzine had no effect on whole brain levels of the amino acid neurotransmitters alanine and gamma-aminobutyric acid, whereas phenelzine caused dramatic increases. Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the transaminase enzymes for gamma-aminobutyric acid and alanine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881457     DOI: 10.1007/bf00169549

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE.

Authors:  R J WURTMAN; J AXELROD
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

Review 2.  Monoamine oxidase inhibitors: rehabilitation from recent research?

Authors:  D Nutt; P Glue
Journal:  Br J Psychiatry       Date:  1989-03       Impact factor: 9.319

3.  Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA).

Authors:  G B Baker; J T Wong; J M Yeung; R T Coutts
Journal:  J Affect Disord       Date:  1991-03       Impact factor: 4.839

4.  A rapid, sensitive assay for gamma-aminobutyric acid in brain using electron-capture gas chromatography.

Authors:  J T Wong; G B Baker; R T Coutts
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1990-10

5.  The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial.

Authors:  E F Marshall; C Q Mountjoy; I C Campbell; R F Garside; I M Leitch; M Roth
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

6.  Acetylator status and response to phenelzine in depressed patients.

Authors:  E C Johnstone; W Marsh
Journal:  Lancet       Date:  1973-03-17       Impact factor: 79.321

7.  Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain.

Authors:  N Popov; H Matthies
Journal:  J Neurochem       Date:  1969-06       Impact factor: 5.372

8.  Parallel changes in the sensitivity of gamma-aminobutyric acid and noradrenergic receptors following chronic administration of antidepressant and GABAergic drugs. A possible role in affective disorders.

Authors:  P D Suzdak; G Gianutsos
Journal:  Neuropharmacology       Date:  1985-03       Impact factor: 5.250

9.  Formation of beta-phenylethylamine from the antidepressant, beta-phenylethylhydrazine.

Authors:  L E Dyck; D A Durden; A A Boulton
Journal:  Biochem Pharmacol       Date:  1985-06-01       Impact factor: 5.858

10.  Metabolic acetylation of phenelzine in rats.

Authors:  A Mozayani; R T Coutts; T J Danielson; G B Baker
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1988-12
View more
  6 in total

Review 1.  Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

Authors:  G B Baker; R T Coutts; K F McKenna; R L Sherry-McKenna
Journal:  J Psychiatry Neurosci       Date:  1992-11       Impact factor: 6.186

2.  The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA.

Authors:  T Paslawski; D Treit; G B Baker; M George; R T Coutts
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition.

Authors:  Erin M MacKenzie; Suzanne L Grant; Glen B Baker; Paul L Wood
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

4.  Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine.

Authors:  A Holt; G B Baker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

Review 5.  Metabolism of monoamine oxidase inhibitors.

Authors:  G B Baker; L J Urichuk; K F McKenna; S H Kennedy
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

6.  Clonidine potentiates the effects of tranylcypromine, phenelzine and two analogues in the forced swimming test in mice.

Authors:  Michel Bourin; Martine Hascoët; Marie Claude Colombel; Ronald T Coutts; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2002-05       Impact factor: 6.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.